Extreme Movers: Perplexity's picks for 2026-10-01
Perplexity picked FICO, CTVA, LQDA, ACN, SNPS for a 1-day horizon. Average directional return: -1.59%. Directions called correctly: 20%.
| Experiment | Extreme Movers |
|---|---|
| Model | Perplexity |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-01 |
| Measured to | 2026-10-02 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | -1.59% |
| Directions called correctly | 20% |
| Benchmark return | +1.38% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | FICO | down | +1.48% | -1.48% | 65% | -2.85% | No |
| 2 | CTVA | up | -0.97% | -0.97% | 60% | -2.35% | No |
| 3 | LQDA | up | +5.47% | +5.47% | 55% | +4.09% | Yes |
| 4 | ACN | up | -10.91% | -10.91% | 70% | -12.29% | No |
| 5 | SNPS | up | -0.06% | -0.06% | 65% | -1.44% | No |
The model's market view
US equities opened mixed on October 1, 2026, with Treasury yields climbing to multi-year highs and investors digesting a softer inflation print alongside Fed policy uncertainty. The session featured extreme dispersion: Corteva plunged ~81% on a mechanical spinoff adjustment (Vylor seed business separation), while Liquidia collapsed ~57% on biotech sector weakness. FICO extended its prior-day 27% crash with another sharp decline on mortgage-scoring competition fears. On the upside, Accenture surged ~23% after strong Q4 earnings, and Synopsys jumped ~12% on AI chip-design partnerships. These moves reflect both substantive corporate events and speculative positioning around regulatory and competitive shifts.
Why each pick
FICO
Fair Isaac fell 26.5% on September 30 after FHFA announced a unified mortgage pricing grid placing VantageScore on equal footing with FICO Classic, while Rocket Mortgage adopted VantageScore 4.0 as its preferred model. The stock trades around $635 intraday on October 1, extending losses. Market cap ~$13B and 20-day average dollar volume exceeds $20M (avg volume ~450K shares at ~$600-900). Catalyst is substantive: structural competitive threat to FICO's mortgage scoring franchise, which underpins a large portion of profits. Direction: down. Hypothesis: continuation, as the regulatory change is permanent and analysts have cut price targets sharply (BofA to $700). Risk: oversold bounce if the market views the 27%+ drop as overdone. Source: https://www.ebc.com/forex/fico-stock-plunges-27-percent-mortgage-scoring-shakeup
CTVA
Corteva dropped ~81% on October 1 due to the completion of its Vylor seed business spinoff, a mechanical adjustment rather than fundamental deterioration. Pre-spin close was $77.65 on September 30; post-spin indicative price is ~$15-20 for the crop-protection-only entity. Market cap was ~$52B pre-spin; post-spin entity likely ~$10-15B. Average daily volume ~4.6M shares at ~$78 equals ~$360M, well above the $20M threshold. The catalyst is non-substantive (accounting adjustment), but the extreme percentage move creates technical volatility. Direction: up. Hypothesis: reversal, as the drop is mechanical and the remaining crop-protection business is fundamentally sound. Risk: confusion over post-spin valuation and potential index rebalancing flows. Note: reference_price reflects pre-spin close as the latest verified regular-session quote; intraday October 1 quotes are unreliable due to the spinoff adjustment. Source: https://www.gurufocus.com/news/9105226/california-court-allows-cortevas-seed-business-spinoff-to-proceed-impacting-ctva-stock
LQDA
Liquidia plunged 57.2% on September 30 to close at $30.26, marking it as the worst-performing healthcare stock in September with a 55% monthly decline. Market cap ~$2.7-3.3B. Average volume ~1.4-1.8M shares; at ~$50-70 pre-crash, 20-day avg dollar volume exceeded $20M. The catalyst appears speculative: broad biotech weakness and concerns about pulmonary hypertension competition, but no specific negative news identified. Direction: up. Hypothesis: reversal, as a 57% single-day drop without company-specific bad news suggests oversold conditions. Risk: continued sector rotation out of biotech or undisclosed fundamental issues. Source: https://www.gurufocus.com/news/9105328/liquidia-corp-lqda-leads-september-2026-healthcare-declines-with-553-drop
ACN
Accenture surged 23.4% on October 1 after reporting Q4 revenue of $18.7B and annual revenue of $74.2B, beating expectations. Stock traded around $215-226 intraday. Market cap ~$130-140B. Average volume ~3-4M shares at ~$180-220 equals ~$600M+, well above $20M. Catalyst is substantive: strong earnings and AI-driven demand for consulting services. Direction: up. Hypothesis: continuation, as earnings beats often lead to multi-day momentum, especially with AI tailwinds. Risk: profit-taking after a large gap-up or broader market weakness. Source: https://www.morningstar.com/markets/movers
SNPS
Synopsys rose 12.4% on October 1, trading around $477-489 intraday, following new AI alliances with OpenAI and Amazon on chip-design tools. Market cap ~$80B. Average volume ~1.5-2M shares at ~$435-485 equals ~$700M+, exceeding $20M threshold. Catalyst is substantive: strategic partnerships validate Synopsys's AI-driven EDA tools and open new revenue streams. Direction: up. Hypothesis: continuation, as AI chip-design demand is a multi-year trend and partnerships with hyperscalers are credible growth drivers. Risk: valuation concerns after a sharp move or broader tech weakness. Source: https://simplywall.st/stocks/us/tech/nyse-jbl/jabil/news/us-stock-market-today-sp-500-futures-edge-higher-as-traders-4/amp
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| GPT-5.6 Sol | UTHR, JBL, LQDA, FORM, ZETA | -0.68% | 40% |
| Muse Spark 1.1 | ACN, VICR, JBL, LQDA, UTHR | -1.90% | 20% |
| Claude Sonnet 5.5 | UTHR, ROG, JBL, FORM, LQDA | +1.42% | 60% |
| Gemini 1.5 Pro | ROG, UTHR, JBL, FORM, ZETA | +2.92% | 100% |
| DeepSeek | HPE, UTHR, FORM, FICO, CEG | +0.21% | 40% |
Written up on ForecastNest Insights: Extreme Movers: Perplexity's picks for 2026-10-01.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.